What do systematic reviews say?

Renin‐angiotensin system inhibition vs placebo or no treatment

The review found no eligible studies for this question.

• Non‐immunosuppressive treatment for IgA nephropathy 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Tonsillectomy plus standard care vs usual care

The review found no eligible studies for this question.

• Non‐immunosuppressive treatment for IgA nephropathy 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Angiotensin‐converting enzyme inhibitors vs placebo

Angiotensin‐converting enzyme inhibitors showed no clear difference in death (any cause) compared with placebo (low certainty).

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3)… 2023 · Cochrane Headline outcomes only
  RR 2 [0.26, 15.37]
  2 studies · 8873 participants
  Low

Angiotensin receptor blockers (ARBs) vs placebo

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3)… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 226 participants
  GRADE not reported

Angiotensin‐converting enzyme inhibitors vs ARB

The review found no eligible studies for this question.

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3)… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Antioxidants vs control

Antioxidants showed no clear difference in death (any cause) compared with control (moderate certainty).

• Antioxidants for adults with chronic kidney disease 2023 · Cochrane Headline outcomes only
  RR 0.95 [0.82, 1.11]
  45 studies · 7530 participants
  Moderate

Low protein diet vs normal protein diet

Low protein diet showed no clear difference in death (any cause) compared with usual or unrestricted protein diet (low certainty).

• Protein restriction for diabetic kidney disease 2023 · Cochrane Headline outcomes only
  RR 0.38 [0.1, 1.44]
  5 studies · 358 participants
  Low

Antiplatelet agent vs control

Antiplatelet agents showed no clear difference in death (any cause) compared with control (low certainty).

• Antiplatelet agents for chronic kidney disease 2022 · Cochrane Headline outcomes only
  RR 0.94 [0.84, 1.06]
  35 studies · 18241 participants
  Low

Exercise vs no exercise or placebo exercise

It is very uncertain whether any exercise changes death (any cause compared with no exercise or placebo exercise (very low certainty).

• Exercise training for adults undergoing maintenance dialysis 2022 · Cochrane Headline outcomes only
  RR 0.95 [0.56, 1.62]
  1 study · 296 participants
  Very low

Resistance training vs no exercise or placebo exercise

The review found no eligible studies for this question.

• Exercise training for adults undergoing maintenance dialysis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aerobic exercise and strength training vs no exercise or placebo exercise

The review found no eligible studies for this question.

• Exercise training for adults undergoing maintenance dialysis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aerobic exercise vs no exercise or placebo exercise

It is very uncertain whether aerobic exercise changes death (any cause) compared with no exercise or placebo exercise (very low certainty).

• Exercise training for adults undergoing maintenance dialysis 2022 · Cochrane Headline outcomes only
  RR 0.95 [0.56, 1.62]
  1 study · 296 participants
  Very low

Resistance training vs another form of resistance (anaerobic) exercise training

• Exercise training for adult lung transplant recipients 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 83 participants
  Very low

Multimodal exercise training vs usual care or no exercise training

• Exercise training for adult lung transplant recipients 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 40 participants
  Very low

Fourteen‐weeks vs 7‐weeks multimodal exercise training

• Exercise training for adult lung transplant recipients 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 66 participants
  Very low

Resistance training vs usual care or no exercise training

The review found no eligible studies for this question.

• Exercise training for adult lung transplant recipients 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Bovine colostrum vs placebo

The review found no eligible studies for this question.

• Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Synsorb Pk vs placebo

The review found no eligible studies for this question.

• Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Urtoxazumab (3.0 mg/kg) vs placebo

It is very uncertain whether urtoxazumab (3.0 mg/kg) changes death (any cause) compared with placebo (very low certainty).

• Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  RR 0.34 [0.01, 8.14]
  1 study · 71 participants
  Very low

Urtoxazumab (1.0 mg/kg) vs placebo

It is very uncertain whether urtoxazumab (1.0 mg/kg) changes death (any cause) compared with placebo (very low certainty).

• Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  RR 0.95 [0.06, 14.59]
  1 study · 74 participants
  Very low